In recent times Emergent BioSolutions(NYSE: EBS) has received national press for playing a major role in fighting the COVID-19 pandemic. The Gaithersburg biotech has been the go-to-firm for companies such as Novavax (Nasdaq: NVAX) and Johnson and Johnson (NYSE: JNJ); and will manufacture the COVID-19 vaccines developed by them.
But Emergent BioSolutions is far more than just a COVID-19 vaccine manufacturer and has a growing array of products in its disease-fighting arsenal. Today the company announced approval from the U.S. Food and Drug Administration (FDA) for an upgrade to its opioid treatment.
Emergent’s Narcan Nasal Spray was approved for a shelf-life extension from 24 months to 36 months. Emergent says it was the first intranasal form of naloxone not only approved by FDA but Health Canada.
Naracan is used as an emergency treatment of opioid overdose. In 2018 there were 67,367 drug overdose related deaths in the United States and 2,087 deaths in Maryland.